** Shares of medtech company TransMedics Group TMDX.O down ~2% at $63 premarket
** Brokerage J.P.Morgan downgrades stock to "neutral" from "overweight", cuts PT to $75 from $116
** Says smaller mid-cap growth stories need to demonstrate meaningful near-term upside to outperform truly, hence the rating
** Says near-term outlook less certain as questions remain on the softness seen in Q3 and present Q4 so far, a setup further complicated by a back-end-loaded 2025 sales growth guide that looks more achievable than beatable
** Says co's 20%-to-25% sales growth forecast for 2025, which co announced on its investor day on Dec. 10, already reflects improving trends for both the market and TMDX, with less obvious upside left on the table
** Seven of 10 brokerages rate the stock "buy" or higher, and three "hold"; with a median PT of $112 - LSEG data
** Up to Monday's close, stock had fallen ~18% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。